实验性自身免疫性脑脊髓炎
体内
髓鞘少突胶质细胞糖蛋白
免疫系统
免疫耐受
免疫学
抗原
树突状细胞
化学
医学
生物
生物技术
作者
Xue Gao,Xiuxiu Cong,He Li,Kuirong Mao,Haorui Wang,Guojiao Lin,Jialiang Wang,Feiqi Liu,Ge Zhu,Huizhu Tan,Yuning Zhang,Liguang Sun,Yong‐Guang Yang,Tianmeng Sun
标识
DOI:10.1002/adtp.202200274
摘要
Abstract Tolerogenic dendritic cells (tDCs) induces regulatory T cell (Treg) differentiation and promotes immune tolerance. However, the effective generation of tDCs in vivo to treat autoimmune diseases remains a significant challenge. In this study, the potential of 1α, 25‐Dihydroxyvitamin D3 (VD3) is explored, which has been shown to promote tDCs differentiation in vitro, to induce tDCs in a mouse model of experimental autoimmune encephalomyelitis (EAE). To overcome the poor solubility of VD3 and induce autoantigen‐specific Tregs, a PLGA‐PEG‐based nano‐drug delivery system is prepared to co‐deliver VD3 and myelin‐oligodendrocyte glycoprotein (MOG) peptides. It is found that intradermal (i.d.) injection of NP/VD3/MOG significantly enhanced the level of antigen‐specific Tregs in vivo. Furthermore, NP/VD3/MOG remarkedly delayed the onset, reduced the severity, and promoted the recovery of EAE mice. This study provides an effective strategy for the treatment of autoimmune diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI